• Pazopanib Hydrochloride: Elevating Translational Cancer Rese

  2026-06-09

  This thought-leadership article explores how mechanistic understanding and strategic assay design with Pazopanib Hydrochloride (GW786034) can empower translational researchers to bridge the gap from in vitro discovery to clinical impact. Integrating recent advances in drug response evaluation, the piece offers practical guidance, competitive insights, and a forward-looking perspective tailored for oncology investigators.

• Anlotinib Hydrochloride in IADSRCT: Case Evidence and Resear

  2026-06-08

  This article reviews the first reported use of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in treating intra-abdominal desmoplastic small round cell tumors (IADSRCT). The reference study demonstrates meaningful tumor regression with manageable toxicity, providing new insights for research into rare and aggressive sarcoma therapies.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-06-08

  Schwartz’s dissertation demonstrates that conventional in vitro drug response metrics, such as relative viability, conflate proliferative arrest and cell death, potentially obscuring true anti-cancer effects. By distinguishing these processes using fractional viability, the study enables more precise evaluation of cancer therapeutics and informs experimental design for angiogenesis inhibitors like Cediranib (AZD2171).

• MLN4924 HCl Salt: Precision NEDD8-Activating Enzyme Inhibiti

  2026-06-07

  MLN4924 HCl salt empowers researchers to dissect the neddylation pathway with unparalleled selectivity, enabling fine-tuned control in cancer and inflammation models. This article provides stepwise workflow enhancements, real-world troubleshooting, and actionable insights drawn from recent studies and benchmarked protocols.

• Scalable iMSC-EV Production: A Platform for Pulmonary Fibros

  2026-06-06

  This study presents a robust bioreactor-based platform for producing extracellular vesicles from induced mesenchymal stem cells (iMSC-EVs) derived from extended pluripotent stem cells. The innovation overcomes traditional bottlenecks in EV manufacturing, yielding standardized, high-quality vesicles with demonstrated efficacy in a preclinical pulmonary fibrosis model.

• Ruxolitinib Phosphate Blocks Mitochondrial Fission in ATC Ce

  2026-06-05

  This study demonstrates that Ruxolitinib phosphate (INCB018424) induces apoptosis and pyroptosis in anaplastic thyroid carcinoma (ATC) by inhibiting DRP1-mediated mitochondrial fission through JAK1/2-STAT3 pathway modulation. The findings highlight a novel mechanism of action for JAK1/2 inhibitors in aggressive thyroid cancer and suggest new avenues for targeting mitochondrial dynamics in oncology research.

• XPO1 Inhibition Enhances Platinum Sensitivity in GCB-DLBCL

  2026-06-05

  This study demonstrates that inhibition of XPO1 (also known as CRM1) with selinexor significantly sensitizes germinal-center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) cells to platinum-based chemotherapies. The findings reveal mechanistic synergy and support the clinical investigation of XPO1 inhibitor–platinum combinations as salvage regimens for refractory lymphoma.

• Nintedanib (BIBF 1120): Translational Precision in ATRX-Defi

  2026-06-04

  Explore how Nintedanib (BIBF 1120) enables precision research in ATRX-deficient cancers and fibrotic disease. This cornerstone article delivers advanced insight into its mechanistic selectivity, protocol optimization, and the translational significance of receptor tyrosine kinase targeting.

• GPCR Regulation of Kir7.1: Glycosylation-Dependent Channel A

  2026-06-04

  This study reveals that G protein–coupled receptors (GPCRs) modulate the glycosylation and activity of the inwardly rectifying potassium channel Kir7.1 through a mechanism distinct from classical GIRK channel regulation. The findings underscore glycosylation as a critical determinant of Kir7.1 function and suggest new avenues for investigating membrane protein regulation in health and disease.

• Cisplatin in Chemoresistance: Metabolic Reprogramming and Im

  2026-06-03

  Explore the multifaceted role of Cisplatin in cancer research, focusing on how metabolic rewiring and immune microenvironment shape chemoresistance. This article offers a unique lens on DNA crosslinking, apoptosis, and advanced assay strategies for overcoming tumor adaptation.

• Naloxone Hydrochloride: Opioid Receptor Antagonist for Resea

  2026-06-03

  Naloxone hydrochloride is a potent opioid receptor antagonist essential in opioid signaling studies and opioid overdose treatment research. Its high specificity for μ-, δ-, and κ-opioid receptors and robust physicochemical profile make it a gold standard for mechanistic and translational research. APExBIO’s B8208 kit provides high-purity, reproducibility-focused naloxone hydrochloride for advanced laboratory workflows.

• Cefoperazone Sodium Salt: Mechanistic Insight & Translationa

  2026-06-02

  This thought-leadership article explores the mechanistic underpinnings and translational research strategies enabled by Cefoperazone (sodium salt). Integrating comparative evidence, workflow guidance, and strategic perspectives, it advances the conversation beyond standard product content, equipping researchers to confront gram-negative bacterial resistance with both technical rigor and strategic foresight.

• Dual-Action p38α Inhibitors Accelerate Dephosphorylation Dyn

  2026-06-02

  The reference study uncovers how certain p38α MAP kinase inhibitors not only block kinase activity but also enhance dephosphorylation of the activation loop by the phosphatase WIP1. This dual mechanism, supported by structural data, suggests new strategies for designing kinase inhibitors with improved specificity and potency in inflammatory disease models.

• 25-Hydroxycholesterol Drives Immunosuppressive TAM Reprogram

  2026-06-01

  Xiao et al. (2024) reveal how 25-hydroxycholesterol accumulation in tumor-associated macrophages activates lysosomal AMPKα, leading to STAT6-dependent immunosuppressive programming. These findings provide mechanistic insight into the metabolic education of TAMs and highlight CH25H/25HC as actionable immunometabolic checkpoints for enhancing anti-tumor immunity.

• Tofacitinib (CP-690550) in Translational RA Macrophage Resea

  2026-06-01

  This article provides translational researchers with a mechanistic and strategic roadmap for leveraging Tofacitinib (CP-690550) in the study of rheumatoid arthritis (RA) macrophages. By integrating recent breakthroughs on immunometabolism and mitochondrial repair, it delivers actionable guidance on assay optimization and positions APExBIO’s Tofacitinib as a pivotal tool in advanced immune modulation research.

471 records 10/32 page Previous Next First page 上5页 678910 下5页 Last page